Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, Versus Placebo in Scalp, Nail, and Palmoplantar Psoriasis: Subset Analyses of the Phase 3 POETYK PSO-1 and PSO-2 Trials. J of Skin 2022, 6 (4), s41. https://doi.org/10.25251/skin.6.supp.41.